These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy].
    Author: Branten AJ, Wetzels JF.
    Journal: Ned Tijdschr Geneeskd; 1998 Dec 26; 142(52):2832-8. PubMed ID: 10065257.
    Abstract:
    Prednisone monotherapy is the treatment of choice for patients with a nephrotic syndrome due to minimal change glomerulopathy. In adult patients treatment should be continued for at least 24 weeks. Within this period a remission of proteinuria will occur in 75 to 90% of the patients. Patients who do not respond satisfactorily to prednisone treatment can be treated with alkylating agents. Cyclophosphamide is the drug used most commonly. Prolonged treatment (> 12 weeks) is associated with a high risk of infertility. If alkylating agents cannot be used, prolonged treatment with ciclosporine is an option.
    [Abstract] [Full Text] [Related] [New Search]